Skip to main content
. 2024 Nov 15;16(11):4392–4401. doi: 10.4251/wjgo.v16.i11.4392

Table 3.

Tumor response of different programmed cell death 1 inhibitor groups, n (%)

PD-1 inhibitor
CR
PR
SD
PD
P value
Tislelizumab 2 (14.3) 5 (35.7) 4 (28.6) 3 (24.1) 0.927
Sintilimab 1 (5.9) 10 (58.8) 5 (29.4) 1 (5.9)
Camrelizumab 6 (13.3) 17 (37.8) 14 (31.1) 8 (17.8)
Toripalimab 4 (14.3) 12 (42.9) 8 (28.5) 4 (14.3)

PD-1: Programmed cell death 1; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.